glp-1 obesity drug news today sep 30 2025 Overdoses Are Rising as Telehealth Weight-Loss Prescriptions Boom Amgen Reshapes the Obesity Drug

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake

Explore BPS Biosciences solutions for GLP-1R research in diabetes

For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

Now it has been shown that limited experimental data can be used to train sophisticated machine learning models to accurately predict the activity of previously uncharacterized peptide ligand variants.

Most users see best results with consistent, daily use over 812 weeks